Skip to main content
Category

Custom Manufacturing

CAR-T cancer, technology, chemotherapyCustom Manufacturingdisease, researchgenetic sequencing,, drug development
February 18, 2025

CAR-T

Introduction: Chimeric Antigen Receptor (CAR) T-cell therapy is advancing cancer treatment with a personalized approach that reprograms a patient’s own immune cells to target and kill cancer cells. Originally developed for hematologic malignancies, CAR-T therapy has shown strong promise in treating otherwise difficult cancers. This therapy presents a unique opportunity for the development of novel oncological and immunotherapy drugs. T-cells are harvested from a patient’s blood sample, and a viral or non-viral vector is used to introduce the genetic instructions to create the CAR. The vector is a delivery system that introduces the CAR gene, enabling the cell to produce these specific receptors. After these trained cells multiply, they are reintroduced into the patient and multiply in the bloodstream. These cells are now able to detect cancer cells that have hidden from standard immune identification. Development: CAR-T therapy has evolved from a long lineage of immunotherapy milestones—from 19th-century bacterial-based approaches such as Coley’s Toxins and BCG vaccine studies to modern…
Jason Kaimana 0
Love0
The Rise of GLP-1 Drugs Custom Manufacturingdisease, researchgenetic sequencing,, drug developmenthealth, diet
January 16, 2025

The Rise of GLP-1 Drugs

The Rise of GLP-1 Drugs  Glucagon-like peptide-1(GLP-1) agonist drugs have emerged as one of the most significant breakthroughs in recent pharmaceutical history. Designed for managing Type 2 diabetes, these drugs have made news headlines and skyrocketed in popularity for their effectiveness in weight loss.   Transition from Diabetes to Weight Loss:  The GLP-1 hormone was first identified by researchers at Massachusetts General Hospital in 1986 as a glucagon precursor. This quickly found commercial applications for managing conditions such as diabetes with Novo Nordisk developing liraglutide in 1990s. This eventually led to the development of semaglutide in 2012, with a similar mechanism of action, but slower onset of effect and longer duration of action. Initially designed for diabetes treatment, the FDA approved Ozempic in 2017. Researchers noted in clinical trials that participants lost 10-15% of their body weight, prompting further applications for weight loss and obesity. Wegovy, another semaglutide-based formulation, uses a higher dose specifically for weight loss and achieved FDA approval…
Jason Kaimana 0
Love0
Close Menu